Health Economics›Anaplastic glioma›Recurrent disease salvage therapy

Recurrent disease salvage therapy

Anaplastic glioma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	—	~9.0 mo	—	—	2
Carboplatin and Bevacizumab Variant #01	—	R 20 108	28d	—	—	—	—	—
Irinotecan and Bevacizumab Variant #01	—	R 19 884	14d	—	—	—	—	—
Temozolomide monotherapy Variant #13	—	R 8 153	28d	—	~8.6 mo	—	—	1
Etoposide monotherapy Variant #01	—	R 2 872	28d	—	—	—	—	—
PCV Variant #01 Partial	—	R 389	42d	—	~49.8 mo	—	—	2
Cyclophosphamide monotherapy N/A - secondary systemic drug	—	R 60	28d	—	~15.8 mo	—	—	1
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	~2.3 mo	~8.5 mo	~2	~R 95 PFS proxy · indirect	19
Radiation therapy N/A - radiation Partial	—	—	49d	~46.0 mo	~7.5 mo	~29	—	8

9 of 9 regimens shown